Novartis Ag (NVS) Total Liabilities (2009 - 2025)
Novartis Ag recorded quarterly Total Liabilities of $64.4 billion in Q4 2025, up 3.3% quarter-over-quarter from $62.3 billion in Q2 2025, and up 10.81% year-over-year from $58.1 billion in Q4 2024.
Novartis Ag's Total Liabilities history runs 13 years deep, the most recent figure standing at $64.4 billion for Q4 2025.
- In Q4 2025, Total Liabilities rose 10.81% year-over-year to $64.4 billion; the TTM figure through Dec 2025 stood at $64.4 billion (up 10.81% YoY), while the FY2025 annual figure was $64.4 billion, up 10.81% from the prior year.
- Total Liabilities came in at $64.4 billion for Q4 2025 at Novartis Ag, up from $62.3 billion in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $64.4 billion in Q4 2025 to a low of -$64.0 billion in Q2 2021.
- A 5-year average of $35.3 billion and a median of $58.1 billion in 2022 frame the typical range for Total Liabilities.
- Across the five-year window, Total Liabilities retreated 10.04% in 2021 and surged 201.75% in 2023, its largest moves.
- Novartis Ag's Total Liabilities stood at $64.0 billion in 2021, then fell by 9.29% to $58.0 billion in 2022, then dropped by 8.33% to $53.2 billion in 2023, then climbed by 9.26% to $58.1 billion in 2024, then gained by 10.81% to $64.4 billion in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $64.4 billion, $62.3 billion, and $58.1 billion for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 85.38 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 119.71 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 143.08 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 82.75 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 66.37 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 60.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 64.40 Bn |
| Jun 30, 2025 | 62.34 Bn |
| Dec 31, 2024 | 58.12 Bn |
| Jun 30, 2024 | 55.60 Bn |
| Dec 31, 2023 | 53.20 Bn |
| Jun 30, 2023 | 59.05 Bn |
| Dec 31, 2022 | 58.03 Bn |
| Jun 30, 2022 | -58.03 Bn |
| Dec 31, 2021 | 63.97 Bn |
| Jun 30, 2021 | -63.97 Bn |
| Dec 31, 2020 | 71.11 Bn |
| Jun 30, 2020 | -75.39 Bn |
| Dec 31, 2019 | 62.82 Bn |
| Jun 30, 2019 | 64.79 Bn |
| Dec 31, 2018 | 66.87 Bn |
| Jun 30, 2018 | 65.16 Bn |
| Dec 31, 2017 | 58.85 Bn |
| Dec 31, 2016 | 55.23 Bn |
| Dec 31, 2015 | -77.12 Bn |
| Mar 31, 2010 | 40,579,000.00 Bn |
| Dec 31, 2009 | 38,043.00 |
| Sep 30, 2009 | 37,373.00 |
| Jun 30, 2009 | 33,786.00 |
| Mar 31, 2009 | 31,742.00 |